REGULATORY

MHLW Device Review Chief Pledges Evidence-Based Approvals amid Diversifying Technologies

By Sakura Kono August 6, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

With new technologies―from software-based devices to regenerative medicine products―reshaping the healthcare landscape, the Ministry of Health, Labor and Welfare (MHLW) aims to maintain rigorous, evidence-based reviews while adapting to an increasingly diverse array of modalities. Yumiko Nomura, new director of…

To read the full story

MHLW Shuffles Senior Bureaucrats, Miyamoto to Head Pharma Safety Bureau
July 2, 2025

REGULATORY

Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026
MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
March 3, 2026
MHLW Details New Operational Rules for Conditional Approvals from May
March 3, 2026
MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…